Dicot AB Year-End Report 2023

Press release: Uppsala, Sweden, February 26, 2024. Dicot AB (publ) publishes its year-end report for the financial year 2023 and for the fourth quarter. The year-end report is available as an attached document and on the company's website www.dicot.se.

Fourth quarter, October-December 2023

• Net sales amounts to KSEK 0 (0)
• Earnings after financial items amounts to KSEK -15,661 (-8,604)
• Earnings per share amounts to SEK -0.02 (-0.06)

Financial year January-December 2023

• Net sales amounts to KSEK 0 (0)
• Earnings after financial items amounts to KSEK -44,157 (-31,756)
• Earnings per share amounts to SEK -0.08 (-0.26)

 

”Getting these positive study results feels like a validation of the quality of last year’s development work. From the conclusion of preclinical studies in the spring, preparations for clinical trials, obtained regulatory approvals, to the launch in August. And all according to a timeline we publicly disclosed back in 2022”, says Elin Trampe, CEO.

 

Significant events during the quarter

• Second part of the Phase 1 study, Multiple Ascending Dose, is initiated
• The first part of the phase 1 study, Single Ascending Dose, can be completed earlier than planned
• The warrants of series TO5 are subscribed to 85.4% which adds gross 16.5 MSEK
• Dicot's preclinical program is presented at SMSNA, North America's largest sexual medicine conference

 

Significant events after the quarter

• Positive results from the first part of the phase 1 study are presented; showing a very good safety profile, no serious side effects, and a good exposure in the body
• Patent application is filed for a new manufacturing method of the starting material through cell culture
• The preclinical research results are presented at the European Society for Sexual Medicine

For further information, please contact:

Elin Trampe, CEO Björn Petersson, CFO

Phone: +46 72 502 1010       Phone: +46 76 109 0000

E-mail: [email protected]       E-mail: [email protected]

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 5,000 shareholders. For more information, please visit www.dicot.se.

 

This information is information that Dicot AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the contact person set out above, on February 26, 2024, at 15.00 CET.

This disclosure contains information that Dicot AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-02-2024 15:00 CET.